Joseph M. Grindel

750 total citations
22 papers, 439 citations indexed

About

Joseph M. Grindel is a scholar working on Pharmacology, Pharmacology and Molecular Biology. According to data from OpenAlex, Joseph M. Grindel has authored 22 papers receiving a total of 439 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pharmacology, 6 papers in Pharmacology and 5 papers in Molecular Biology. Recurrent topics in Joseph M. Grindel's work include Antibiotics Pharmacokinetics and Efficacy (5 papers), Drug-Induced Hepatotoxicity and Protection (4 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Joseph M. Grindel is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (5 papers), Drug-Induced Hepatotoxicity and Protection (4 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Joseph M. Grindel collaborates with scholars based in United States, Belgium and Italy. Joseph M. Grindel's co-authors include R. Emanuele, Balasubramanian Mythili Gnanamangai, Olga Piraner, Bruce H. Migdalof, Judith K. Marquis, Lennette J. Benjamin, Lee Hilliard, Beatrice Files, Lori Luchtman‐Jones and Thomas D. Coates and has published in prestigious journals such as Annals of the New York Academy of Sciences, Journal of Medicinal Chemistry and Molecular Pharmacology.

In The Last Decade

Joseph M. Grindel

22 papers receiving 412 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joseph M. Grindel United States 11 134 71 63 53 51 22 439
Takeshi Goromaru Japan 13 132 1.0× 43 0.6× 19 0.3× 26 0.5× 37 0.7× 34 399
Mark Wirth United States 9 190 1.4× 44 0.6× 14 0.2× 59 1.1× 75 1.5× 9 663
Frederike K. Engels Netherlands 13 138 1.0× 118 1.7× 45 0.7× 82 1.5× 131 2.6× 17 681
Karel J. Lambert United States 9 119 0.9× 33 0.5× 17 0.3× 26 0.5× 58 1.1× 10 463
R. Emanuele Italy 12 95 0.7× 16 0.2× 72 1.1× 14 0.3× 77 1.5× 29 539
Csaba Révész Hungary 13 166 1.2× 55 0.8× 11 0.2× 13 0.2× 52 1.0× 29 643
Taiji Sawamoto Japan 17 100 0.7× 60 0.8× 16 0.3× 51 1.0× 10 0.2× 30 644
Y Bertrand France 13 138 1.0× 18 0.3× 63 1.0× 8 0.2× 31 0.6× 34 536
Betty S. van der Veen Netherlands 7 172 1.3× 35 0.5× 21 0.3× 19 0.4× 12 0.2× 13 693

Countries citing papers authored by Joseph M. Grindel

Since Specialization
Citations

This map shows the geographic impact of Joseph M. Grindel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph M. Grindel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph M. Grindel more than expected).

Fields of papers citing papers by Joseph M. Grindel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph M. Grindel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph M. Grindel. The network helps show where Joseph M. Grindel may publish in the future.

Co-authorship network of co-authors of Joseph M. Grindel

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph M. Grindel. A scholar is included among the top collaborators of Joseph M. Grindel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph M. Grindel. Joseph M. Grindel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ballas, Samir K., Beatrice Files, Lori Luchtman‐Jones, et al.. (2006). Secretory Phospholipase A2Levels in Patients with Sickle Cell Disease and Acute Chest Syndrome. Hemoglobin. 30(2). 165–170. 27 indexed citations
2.
Ballas, Samir K., Beatrice Files, Lori Luchtman‐Jones, et al.. (2004). Safety of Purified Poloxamer 188 in Sickle Cell Disease: Phase I Study of a Non‐ionic Surfactant in the Management of Acute Chest Syndrome. Hemoglobin. 28(2). 85–102. 43 indexed citations
3.
Mani, Sridhar, Sanjay Goel, Maria Nesterova, et al.. (2003). Clinical Studies in Patients with Solid Tumors using a Second‐Generation Antisense Oligonucleotide (GEM®231) Targeted against Protein Kinase A Type I. Annals of the New York Academy of Sciences. 1002(1). 252–262. 29 indexed citations
4.
Grindel, Joseph M., et al.. (2002). Distribution, Metabolism, and Excretion of a Novel Surface‐Active Agent, Purified Poloxamer 188, in Rats, Dogs, and Humans. Journal of Pharmaceutical Sciences. 91(9). 1936–1947. 100 indexed citations
5.
Grindel, Joseph M., et al.. (2002). Pharmacokinetics of a novel surface‐active agent, purified poloxamer 188, in rat, rabbit, dog and man. Biopharmaceutics & Drug Disposition. 23(3). 87–103. 52 indexed citations
6.
Marquis, Judith K. & Joseph M. Grindel. (2000). Toxicological evaluation of oligonucleotide therapeutics.. PubMed. 2(3). 258–63. 20 indexed citations
7.
Meuldermans, W., et al.. (1984). Plasma levels, biotransformation and excretion of oxatomide (R 35 443) in rats, dogs and man. Xenobiotica. 14(6). 445–462. 8 indexed citations
8.
Grindel, Joseph M., et al.. (1983). Reversed-phase high-performance liquid chromatographic assay for zomepirac in urine. Journal of Chromatography B Biomedical Sciences and Applications. 272(1). 210–215. 3 indexed citations
9.
Grindel, Joseph M.. (1981). The Pharmacokinetic and Metabolic Profile of the Antiinflammatory Agent Tolmetin in Laboratory Animals and Man. Drug Metabolism Reviews. 12(2). 363–377. 7 indexed citations
10.
Wu, W. N., et al.. (1980). The metabolism of zomepirac sodium. II. Isolation and identification of the urinary metabolites in rat, mouse, rhesus monkey, and man.. Drug Metabolism and Disposition. 8(5). 349–352. 16 indexed citations
11.
Grindel, Joseph M., et al.. (1980). The metabolism of zomepirac sodium. I. Disposition in laboratory animals and man.. Drug Metabolism and Disposition. 8(5). 343–348. 24 indexed citations
12.
Grindel, Joseph M., et al.. (1980). Review of the Pharmacokinetics and Metabolism of Zomepirac in Man and Animals. The Journal of Clinical Pharmacology. 20(4). 223–229. 17 indexed citations
13.
Grindel, Joseph M., et al.. (1979). Characterization of a New Urinary Metabolite of Penfluridol in the Rat, Rabbit, Dog, and Man. Drug Metabolism and Disposition. 7(6). 448–448. 3 indexed citations
14.
Grindel, Joseph M., et al.. (1979). Absorption and excretion of tolmetin in arthritic patients. Clinical Pharmacology & Therapeutics. 26(1). 122–128. 17 indexed citations
15.
Grindel, Joseph M., et al.. (1979). The comparative metabolism and disposition of penfluridol-3H in the rat, rabbit, dog, and man.. Drug Metabolism and Disposition. 7(5). 325–329. 10 indexed citations
16.
Grindel, Joseph M., et al.. (1977). Quantitation of the Antimalarial Agent, Mefloquine, in Blood, Plasma, and Urine Using High-Pressure Liquid Chromatography. Journal of Pharmaceutical Sciences. 66(6). 834–837. 29 indexed citations
17.
18.
19.
Grunewald, Gary L., Joseph M. Grindel, William C. Vincek, & Ronald T. Borchardt. (1975). Importance of the Aromatic Ring in Adrenergic Amines. Molecular Pharmacology. 11(5). 694–699. 2 indexed citations
20.
Grunewald, Gary L., Joseph M. Grindel, William C. Vincek, & Ronald T. Borchardt. (1975). Importance of the aromatic ring in adrenergic amines. Nonaromatic analoques of phenylethanolamine as substrates for phenylethanolamine N-methyltransferase.. PubMed. 11(5). 694–9. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takeshi Goromaru Breakdown of academic impact, for papers by Mark Wirth Breakdown of academic impact, for papers by Frederike K. Engels Breakdown of academic impact, for papers by Karel J. Lambert Breakdown of academic impact, for papers by R. Emanuele Breakdown of academic impact, for papers by Csaba Révész Breakdown of academic impact, for papers by Taiji Sawamoto Breakdown of academic impact, for papers by Y Bertrand Breakdown of academic impact, for papers by Betty S. van der Veen
Rankless by CCL
2026